Head and neck cancer is the 6th most common malignancy worldwide and urgently requires
novel therapy methods to change the situation of low 5-years survival rate and poor …

In head and neck squamous cell carcinoma (HNSCC), data from studies using checkpoint-
inhibiting antibodies that target programmed death 1 (PD-1) or its ligand the programmed …

Background There are still few data on the activity and safety of cetuximab-based salvage
chemotherapy after immunotherapy (SCAI) in patients with squamous cell cancer of the …

Objective To examine the effects of oral cancer-derived exosomes (OCEXs) on natural killer
(NK) cells and to explore the underlying mechanism. Materials and Methods OCEXs were …

Objective Although nivolumab treatment is effective in extending the overall survival (OS) in
patients with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M …

Objectives To assess the real‐world clinical benefit of re‐challenging chemotherapy after
pembrolizumab in patients with metastatic urothelial carcinoma (mUC), as there have been …

Immunotherapy with PD-1 inhibitors monotherapy or combined with chemotherapy
comprises the first-line palliative treatment for patients with recurrent or metastatic head and …

Background The purposes of this study were to describe the characteristics of a prospective
multicenter series of patients with salivary duct carcinoma and to investigate prognostic …

Patients with metastatic squamous cell cancer of the head and neck (SCCHN) have a poor
prognosis, with most patients surviving less than a year. Immunotherapy (IO) is changing the …

Infusion reaction is an adverse event of therapeutic monoclonal antibodies. Nivolumab, an
anti‐programmed death‐1 antibody, directly activates T cells, which could probably interact …